A study led by the Science and Technology Facilities Council (STFC) Central Laser Facility (CLF) has demonstrated for the first time that a crucial interface in a protein that drives EGFR resistance to targeted cancer therapies could act as a target for more effective treatments. This research, published in Nature…

AstraZeneca notched another win with its tyrosine kinase inhibitor Tagrisso (osimertinib) in early-stage, non-small cell lung cancer. In the ADUARA trial, overall survival (OS) was doubled with Tagrisso compared to placebo. The trial comprised patients with epidermal growth factor receptor-mutated (EGFRm) positive tumors who were treated after surgery. The final…

Originally Aired: May 18, 2023Time: 8:00 am PT, 11:00 am ET, 17:00 CET VIEW NOW SHORTLY To be implemented in the clinic, tests must be validated and approved through a regulatory process. Coverage and procedures for mutation types vary among the many available tests. There are various methods for EGFR mutation detection,…

CD70 is highly expressed on drug-resistant cancer cells in EGFR-mutant non-small cell lung cancer (NSCLC) representing a promising new target for treatment of cancer cells that remain after a patient receives EGFR tyrosine kinase inhibitor (TKI) therapy. The new research from investigators at The University of Texas MD Anderson Cancer…

Grouping epidermal growth factor receptor (EGFR) mutations by structure and function can be used to better match non-small cell lung cancer (NSCLC) patients to the most promising treatments, according to researchers from The University of Texas MD Anderson Cancer Center. The findings, published today in Nature, identify four subgroups of mutations and introduce…

Approximately 15% of non-small cell lung cancers have a mutation in a growth receptor called EGFR, causing tumor cells to grow uncontrollably. Researchers developed an effective drug that inhibits EGFR and kills cancer cells. However, the tumors can grow back. A team at Cold Spring Harbor Laboratory (CSHL) wanted to…

Low levels of a protein called p120 catenin, thought to help prevent tumor formation, may explain why some patients develop resistance to EGFR targeted cancer therapy. In an early-stage study carried out using cancer cell lines, researchers based at the Penn State University College of Medicine showed that cells with…

Fluxion Biosciences has launched three new targeted NGS liquid biopsy panels: Spotlight Myeloid, Spotlight EGFR, and Spotlight TP53. The new panels complement the company’s Spotlight 59 pan-cancer panel, and have been validated with Fluxion’s ERASE-Seq variant caller. Spotlight Myeloid is a 478-amplicon panel covering 23 clinically-relevant genes implicated in acute…

Trovagene said it will provide its Trovera urine ctDNA biomarker test and services to AstraZeneca, under an agreement whose value was not disclosed. Tovagene’s Trovera EGFR urine liquid biopsy test will initially be used in an open-label prospective biomarker study designed to evaluate whether the combination of noninvasive urine and…

In an advance for AI in drug discovery, SOPHiA GENETICS, in collaboration with AstraZeneca, recently presented data generated using multimodal machine learning models to identify subgroups of stage IV non-small cell lung cancer (NSCLC) patients who could most benefit from a specific treatment—the addition of tremelimumab to durvalumab and chemotherapy.…

A survey by the International Association for the Study of Lung Cancer (IASLC) has shown that although lung cancer biomarker testing rates have increased substantially since 2018, they remain suboptimal, particularly for patients with early-stage disease. Cost, time, sample quality, access to testing, and a lack of awareness were the…

A team of investigators from Notre Dame has developed a blood-based test that they say can diagnose glioblastoma in less than an hour. The new diagnostic uses an electrokinetic technology that is capable of detecting epidermal growth factor receptors (EGFRs), which are known to be overexpressed in glioblastoma and other…

Researchers at the Fujita Health University in Japan report that adding a measure of how well kidneys are filtering blood called estimated glomerular filtration rate (eGFR) to an existing risk measure can more accurately predict sudden cardiac death (SCD) in patients with congestive heart failure. This new measure of risk,…

Scorpion Therapeutics has closed a $150 million series C  to support development of its precision oncology pipeline, including lead compound STX-478—a highly specific PI3Kα inhibitor. The financing was co-led by Frazier Life Sciences and Lightspeed Venture Partners and included additional new support from Willett Advisors and leading healthcare institutional investors,…

Despite extensive research into the genomic anomalies of glioblastoma (GBM) over the past decade, the five-year survival rate remains under five percent. To address this, researchers led by a team of proteogenomic experts from Washington University studied high-grade gliomas—which includes both IDH-wildtype GBM and IDH-mutant grade 4 astrocytoma—using various molecular…